<--- Back to Details
First PageDocument Content
Vesicular stomatitis virus / Oncolytic virus / Glioma / Viral vector / Glioblastoma multiforme / Immune system / Green fluorescent protein / Metastasis / Oncovirus / Medicine / Biology / Brain tumor
Date: 2008-02-20 13:30:49
Vesicular stomatitis virus
Oncolytic virus
Glioma
Viral vector
Glioblastoma multiforme
Immune system
Green fluorescent protein
Metastasis
Oncovirus
Medicine
Biology
Brain tumor

1882 • The Journal of Neuroscience, February 20, 2008 • 28(8):1882–1893 Neurobiology of Disease

Add to Reading List

Source URL: www.jneurosci.org

Download Document from Source Website

File Size: 1,14 MB

Share Document on Facebook

Similar Documents

Final Results of a Phase II Multicenter Trial of HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab Combination Treatment in Patients with Stage IIIB-IV Unresectable or Metastatic Melanoma Abstract #1664

Final Results of a Phase II Multicenter Trial of HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab Combination Treatment in Patients with Stage IIIB-IV Unresectable or Metastatic Melanoma Abstract #1664

DocID: 1v2ur - View Document

Tumor response from Phase II study of combination treatment of intratumoral HF10, a replication - competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melano

Tumor response from Phase II study of combination treatment of intratumoral HF10, a replication - competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melano

DocID: 1uTz9 - View Document

When Patients Win, We All Win™  Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

When Patients Win, We All Win™ Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

DocID: 1rgN5 - View Document

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile.  Photo courtesy of Dina Potter. Sunny Tree. 48

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile. Photo courtesy of Dina Potter. Sunny Tree. 48" × 60".

DocID: 1rePY - View Document

OVC Crestword copy black read

OVC Crestword copy black read

DocID: 1qyO0 - View Document